Tiotropium is widely used for COPD, but patients report highly variable responses to this medication. A clinical trial of severe COPD subjects could address both short-term (bronchodilator effect) and intermediate-term (COPD exacerbations) outcomes of this heterogeneous response by examining radiologic (chest CT), clinical (Six Minute Walk, Spirometry), and pharmacogenetic (GWAS) influences on this heterogeneous response. ...more »
Which programs or program elements are most critical (the “active ingredients”) in improving quality of life, reducing hospitalizations, reducing emergency department visits, and increasing survival?
How can we increase physical activity in our COPD patients?
Further development and clinical usefulness of COPD phenotypes
a. Linking phenotypes to clinically meaningful outcomes
b. Establishing treatment algorithms for different phenotypes
What is the validity of administrative/billing data to evaluate the quality of COPD care as part of quality improvement initiatives? What care practices can be assessed using these data?
Approach, diagnostics and management of asthma-COPD overlap syndrome.
Does a care coordination program improve the detection and treatment of co-morbid depression in patients with COPD?
What is the comparative effectiveness of short-term vs. chronic (indefinite) pulmonary rehabilitation on patient-reported outcomes (symptom frequency, activities of daily living, quality of life, sleep quality, exacerbations)?
How to "cure" a chronic, incurable disease - A potential giant step in saving the lives of many thousands of Americans, and potentially millions worldwide, who are afflicted with COPD, the third leading cause of death in the U.S. The financial effect of COPD in the United States alone is well over $50 billion per year. It is estimated that some 30 million Americans have COPD, which of course means that at least that ...more »
Does a protocol-based screening for commonly occurring comorbid conditions in patients with COPD (eg. CAD, CHF, depression, sleep apnea) improve management and outcomes for patients with COPD?
Azithromycin is very effective at reducing exacerbations in COPD, but we do not understand the biological mechanism, i.e. anitbiotic effect versus antiinflammatory effect. Because we do not understand how it works (and because of the potential for side effects), azithromycin is not yet widely used. Clinical studies designed to answer this question would help us refine our therapeutic approach and may allow us to minimze ...more »
Can Measuring CD31+EMPs predict loss of lung function, provide potential bio marker for accelerated lung function loss, and predict increased risk for atherosclerosis leading to increased risk for cardiovascular events?